The phase III KRYSTAL-10 trial did not meet its co-primary survival endpoints

An ATOMIC study pre-planned exploratory analysis reports no DFS benefit with the addition of immunotherapy in patients receiving fewer than six cycles of chemotherapy

Findings from the EMERALD-1 and EMERALD-3 studies suggest that further evidence of benefit is needed and to reflect on the use of surrogate endpoints

Positive findings are reported for first-line zoldonrasib plus chemotherapy and second-line zoldonrasib plus daraxonrasib in two early-phase studies

Tumours with no ctDNA-identified pathogenic variants for anti-EGFR drug resistance genes appear to respond to continued cetuximab beyond disease progression

Rapid advances in molecular targeting, immunotherapy optimisation and novel drug classes are reshaping gastrointestinal oncology

Every day, clinicians generate thousands of reports containing critical data that will never be analysed. Not because it lacks value — but because extracting it remains a bottleneck.

Long-term dostarlimab data suggest that immunotherapy may be used with curative intent in this difficult-to-treat population

Immunotherapy is optimising outcomes in LACC, with durable responses and long-term survival, especially in those with immune activated or ‘hot’ tumours